ijms-logo

Journal Browser

Journal Browser

Modulation of Autophagic Activity for the Treatment of Alzheimer’s Disease

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 9884

Special Issue Editor


E-Mail Website
Guest Editor
Second Department of Internal Medicine, Division of Neurology, University of Fukui, Fukui, Japan
Interests: Alzheimer’s disease; aggregation; tau oligomer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As neurons age, their survival depends on eliminating a growing burden of damaged, potentially toxic proteins and organelles. This capability declines with aging and disorders. There are two proteolytic systems, the proteasome system and the autophagic–lysosomal system. Senile plaques consist of amyloid β protein (Aβ) and neurofibrillary tangles (NFTs) which, composed of highly phosphorylated tau protein, are pathological hallmarks of Alzheimer's disease (AD).

Autophagy is considered to be one of the main Aβ-eliminating pathways under normal conditions. The ubiquitin proteasomal system may be the primary mechanism to degrade endogenous tau, while aggregated tau does not undergo degradation by the proteasome. Autophagy is involved in the clearance of soluble and aggregated tau and NFT in the cell. Moreover, autophagy activation can reduce the secretion of tau and tau propagation. These facts imply that autophagy activation can be beneficial for the AD via clearance of Aβ or tau. In fact, several therapeutic studies have been performed by modulating autophagy, including mTORC1-dependent and -independent autophagy inducers, other autophagy-inducing drugs, and gene therapy including micro RNA. However, it has been reported that Aβ can be produced in autophagy, and Aβ secretion can also be done by autophagy. This Special Issue will give us precious information about autophagy and Aβ or tau. Additionally, it may shed light on whether autophagy activation is beneficial or not for AD treatment.

Dr. Tadanori Hamano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Alzheimer’s disease
  • tau protein
  • amyloid protein
  • autophagy
  • LC3
  • P62
  • rapamycin
  • mTORC1

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 2696 KiB  
Review
Autophagy and Tau Protein
by Tadanori Hamano, Soichi Enomoto, Norimichi Shirafuji, Masamichi Ikawa, Osamu Yamamura, Shu-Hui Yen and Yasunari Nakamoto
Int. J. Mol. Sci. 2021, 22(14), 7475; https://doi.org/10.3390/ijms22147475 - 12 Jul 2021
Cited by 65 | Viewed by 9476
Abstract
Neurofibrillary tangles, which consist of highly phosphorylated tau protein, and senile plaques (SPs) are pathological hallmarks of Alzheimer’s disease (AD). In swollen axons, many autophagic vacuoles are observed around SP in the AD brain. This suggests that autophagy function is disturbed in AD. [...] Read more.
Neurofibrillary tangles, which consist of highly phosphorylated tau protein, and senile plaques (SPs) are pathological hallmarks of Alzheimer’s disease (AD). In swollen axons, many autophagic vacuoles are observed around SP in the AD brain. This suggests that autophagy function is disturbed in AD. We used a neuronal cellular model of tauopathy (M1C cells), which harbors wild type tau (4R0N), to assess the effects of the lysosomotrophic agent NH4Cl, and autophagy inhibitors chloroquine and 3 methyladenine (3MA). It was found that chloroquine, NH4Cl and 3MA markedly increased tau accumulation. Thus, autophagy lysosomal system disturbances disturbed the degradation mechanisms of tau protein. Other studies also revealed that tau protein, including aggregated tau, is degraded via the autophagy lysosome system. Phosphorylated and C terminal truncated tau were also reported to disturb autophagy function. As a therapeutic strategy, autophagy upregulation was suggested. Thus far, as autophagy modulators, rapamycin, mTOCR1 inhibitor and its analogues, lithium, metformin, clonidine, curcumin, nicotinamide, bexaroten, and torehalose have been proposed. As a therapeutic strategy, autophagic modulation may be the next target of AD therapeutics. Full article
Show Figures

Figure 1

Back to TopTop